Pediatric DDR inhibitor combinations: Are WEE1 there yet?
Cancer · 2023
DOI: 10.1002/cncr.34785 ↗Kurz gefasst
Editorial in der Zeitschrift Cancer, 2023. Verfasst von Emily K Slotkin und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Hauptthemen laut MEDLINE: Pyrimidines, Pyrimidinones. Die Arbeit nennt 20 Literaturangaben. Gefördert von: National Cancer Institute.
Abstract (Originalsprache)
A phase 2 study of the WEE1 inhibitor adavosertib in combination with irinotecan in children demonstrates an intriguing positive signal of efficacy in neuroblastoma, a pediatric tumor characterized by replication stress. Further pediatric development of adavosertib and related compounds targeting DNA damage response will be challenged by appropriate patient selection, fit‐for‐filing trial design, and ongoing access to agents, likely to be predicated on success in adult malignancy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
ORCID-Profile: Emily K Slotkin, Julia L Glade Bender
Förderung
- National Cancer Institute
Zitieren
APA
Slotkin, E. K., Ortiz, M. V., & Glade Bender, J. L. (2023). Pediatric DDR inhibitor combinations: Are WEE1 there yet?. Cancer. https://doi.org/10.1002/cncr.34785
Vancouver
Slotkin EK, Ortiz MV, Glade Bender JL. Pediatric DDR inhibitor combinations: Are WEE1 there yet?. Cancer. 2023. doi:10.1002/cncr.34785
BibTeX
@article{Slotkin2023,
author = {Slotkin, Emily K and Ortiz, Michael V and Glade Bender, Julia L},
title = {Pediatric DDR inhibitor combinations: Are WEE1 there yet?},
journal = {Cancer},
year = {2023},
doi = {10.1002/cncr.34785}
}
EUVIMED